Common Stocks - 97.9%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 92.0%
|
|||
Biotechnology - 92.0%
|
|||
AbbVie, Inc.
|
3,776,938
|
537,798,194
|
|
Abivax SA ADR (a)
|
34,700
|
352,205
|
|
Absci Corp. (a)(b)
|
992,700
|
1,657,809
|
|
Acelyrin, Inc.
|
30,862
|
207,393
|
|
Acelyrin, Inc. (c)
|
1,206,226
|
8,105,839
|
|
Acelyrin, Inc. rights (b)(d)
|
146,574
|
935,728
|
|
Adverum Biotechnologies, Inc. (b)(e)
|
5,871,492
|
4,748,276
|
|
Aerovate Therapeutics, Inc. (a)(b)
|
311,676
|
4,896,430
|
|
Alector, Inc. (b)
|
3,381,076
|
18,325,432
|
|
Alkermes PLC (b)
|
297,636
|
7,184,933
|
|
Allena Pharmaceuticals, Inc. (b)
|
93,683
|
9
|
|
Allogene Therapeutics, Inc. (a)(b)
|
2,277,888
|
5,353,037
|
|
Allovir, Inc. (a)(b)
|
942,101
|
1,771,150
|
|
Alnylam Pharmaceuticals, Inc. (b)
|
656,282
|
110,419,447
|
|
Alpine Immune Sciences, Inc. (b)
|
220,800
|
3,422,400
|
|
ALX Oncology Holdings, Inc. (b)
|
1,136,549
|
8,910,544
|
|
Ambrx Biopharma, Inc.
|
625,148
|
7,214,208
|
|
Amgen, Inc.
|
1,269,113
|
342,203,629
|
|
Amicus Therapeutics, Inc. (b)
|
2,055,800
|
22,654,916
|
|
AnaptysBio, Inc. (a)(b)
|
201,628
|
2,851,020
|
|
Apellis Pharmaceuticals, Inc. (a)(b)
|
1,294,879
|
69,755,132
|
|
Apogee Therapeutics, Inc. (a)
|
378,956
|
7,393,432
|
|
Applied Therapeutics, Inc. (a)(b)
|
2,427,436
|
5,121,890
|
|
Arcellx, Inc. (a)(b)
|
1,192,501
|
62,642,078
|
|
Arcturus Therapeutics Holdings, Inc. (a)(b)
|
831,930
|
19,916,404
|
|
Arcus Biosciences, Inc. (b)
|
2,936,896
|
44,229,654
|
|
Argenx SE ADR (b)
|
177,906
|
80,166,223
|
|
Arrowhead Pharmaceuticals, Inc. (b)
|
854,632
|
18,118,198
|
|
Ars Pharmaceuticals, Inc. (a)(b)
|
1,200,456
|
5,798,202
|
|
Ascendis Pharma A/S sponsored ADR (b)
|
659,409
|
66,224,446
|
|
Astria Therapeutics, Inc. (b)
|
423,413
|
1,968,870
|
|
Astria Therapeutics, Inc. warrants (b)(d)
|
115,136
|
1
|
|
aTyr Pharma, Inc. (b)
|
2,258,063
|
2,935,482
|
|
Aura Biosciences, Inc. (b)
|
356,492
|
2,859,066
|
|
Avidity Biosciences, Inc. (b)
|
374,450
|
2,924,455
|
|
Axcella Health, Inc. (a)(b)
|
66,454
|
65,191
|
|
Beam Therapeutics, Inc. (a)(b)
|
1,023,450
|
28,738,476
|
|
BeiGene Ltd. ADR (b)
|
27,498
|
5,140,476
|
|
Bicycle Therapeutics PLC ADR (a)(b)
|
266,347
|
3,835,397
|
|
BioCryst Pharmaceuticals, Inc. (a)(b)
|
2,581,481
|
15,179,108
|
|
Biogen, Inc. (b)
|
486,336
|
113,841,531
|
|
Biohaven Ltd. (a)(b)
|
2,002,310
|
66,716,969
|
|
Biomea Fusion, Inc. (a)(b)
|
392,829
|
5,919,933
|
|
BioXcel Therapeutics, Inc. (a)(b)
|
274,527
|
1,043,203
|
|
Blueprint Medicines Corp. (b)
|
656,308
|
45,705,289
|
|
BridgeBio Pharma, Inc. (b)
|
1,255,346
|
36,040,984
|
|
BridgeBio Pharma, Inc. (f)
|
733,408
|
21,056,144
|
|
Candel Therapeutics, Inc. (a)(b)
|
298,384
|
268,247
|
|
Cargo Therapeutics, Inc.
|
338,600
|
5,062,070
|
|
Cartesian Therapeutics, Inc. (a)(b)
|
5,385,728
|
7,270,733
|
|
Celldex Therapeutics, Inc. (b)
|
907,200
|
27,406,512
|
|
Centessa Pharmaceuticals PLC ADR (a)(b)
|
2,787,194
|
16,723,164
|
|
Century Therapeutics, Inc. (b)
|
135,018
|
184,975
|
|
Cerevel Therapeutics Holdings (b)
|
717,280
|
18,599,070
|
|
Chinook Therapeutics, Inc. rights (b)(d)
|
115,821
|
1
|
|
Codiak Biosciences, Inc. (a)(b)(d)
|
448,539
|
4
|
|
Codiak Biosciences, Inc. warrants 9/15/27 (b)(d)
|
46,000
|
0
|
|
Cogent Biosciences, Inc. (b)
|
65,800
|
504,686
|
|
Compass Therapeutics, Inc. (a)(b)
|
428,436
|
706,919
|
|
Crinetics Pharmaceuticals, Inc. (b)
|
1,233,050
|
39,198,660
|
|
CRISPR Therapeutics AG (a)(b)
|
177,422
|
11,839,370
|
|
Cyclerion Therapeutics, Inc. (b)
|
41,864
|
90,426
|
|
Cyclerion Therapeutics, Inc. (b)(f)
|
4,740
|
10,238
|
|
Cytokinetics, Inc. (b)
|
794,471
|
26,598,889
|
|
Day One Biopharmaceuticals, Inc. (b)
|
447,733
|
5,184,748
|
|
Denali Therapeutics, Inc. (b)
|
288,969
|
5,351,706
|
|
Dianthus Therapeutics, Inc. (unlisted) (f)
|
129,460
|
1,374,995
|
|
Disc Medicine, Inc. (b)
|
217,090
|
11,979,026
|
|
Disc Medicine, Inc. rights (b)(d)
|
1,555,907
|
16
|
|
Dyne Therapeutics, Inc. (b)
|
180,313
|
1,997,868
|
|
Entrada Therapeutics, Inc. (a)(b)
|
535,105
|
6,940,312
|
|
Exact Sciences Corp. (b)
|
68,200
|
4,364,800
|
|
Exelixis, Inc. (b)
|
1,048,954
|
22,877,687
|
|
Fate Therapeutics, Inc. (b)
|
106,587
|
265,402
|
|
Foghorn Therapeutics, Inc. (b)
|
109,619
|
465,881
|
|
Fusion Pharmaceuticals, Inc. (b)
|
29,002
|
160,671
|
|
Fusion Pharmaceuticals, Inc. (f)
|
1,483,000
|
8,215,820
|
|
Geron Corp. (b)
|
2,948,906
|
5,691,389
|
|
Geron Corp. warrants 12/31/25 (b)
|
2,100,000
|
946,776
|
|
Gilead Sciences, Inc.
|
101,321
|
7,761,189
|
|
Gossamer Bio, Inc. (a)(b)(e)
|
12,162,076
|
9,513,176
|
|
Gritstone Bio, Inc. (b)
|
1,858,676
|
2,416,279
|
|
Halozyme Therapeutics, Inc. (b)
|
83,700
|
3,231,657
|
|
Icosavax, Inc. (b)
|
256,831
|
2,599,130
|
|
Ideaya Biosciences, Inc. (a)(b)
|
916,957
|
28,838,298
|
|
Idorsia Ltd. (a)(b)
|
4,406,581
|
9,641,440
|
|
IGM Biosciences, Inc. (a)(b)(e)
|
1,688,482
|
11,380,369
|
|
Immuneering Corp. (a)(b)
|
489,285
|
3,209,710
|
|
Immunocore Holdings PLC ADR (b)
|
207,718
|
10,952,970
|
|
Immunovant, Inc. (b)
|
891,843
|
34,897,817
|
|
Incyte Corp. (b)
|
6,900
|
374,946
|
|
Inhibrx, Inc. (b)
|
149,109
|
3,096,994
|
|
Inozyme Pharma, Inc. (a)(b)
|
2,267,187
|
8,728,670
|
|
Insmed, Inc. (b)
|
522,992
|
13,085,260
|
|
Intellia Therapeutics, Inc. (b)
|
823,501
|
24,400,335
|
|
Ionis Pharmaceuticals, Inc. (a)(b)
|
966,777
|
47,826,458
|
|
iTeos Therapeutics, Inc. (b)
|
139,700
|
1,307,592
|
|
Janux Therapeutics, Inc. (b)
|
178,348
|
1,556,978
|
|
Karuna Therapeutics, Inc. (b)
|
321,742
|
61,520,288
|
|
Keros Therapeutics, Inc. (b)
|
231,229
|
7,015,488
|
|
Korro Bio, Inc. (f)
|
88,608
|
3,527,883
|
|
Korro Bio, Inc.
|
92,276
|
3,480,558
|
|
Kronos Bio, Inc. (a)(b)
|
365,200
|
434,588
|
|
Krystal Biotech, Inc. (b)(e)
|
1,985,122
|
206,909,266
|
|
Kymera Therapeutics, Inc. (b)
|
532,313
|
11,050,818
|
|
Legend Biotech Corp. ADR (b)
|
460,110
|
27,983,890
|
|
Madrigal Pharmaceuticals, Inc. (a)(b)
|
166,508
|
33,851,076
|
|
MannKind Corp. (a)(b)
|
5,931,201
|
21,470,948
|
|
Merus BV (a)(b)
|
730,453
|
18,071,407
|
|
Mineralys Therapeutics, Inc. (a)
|
29,900
|
199,134
|
|
Minerva Neurosciences, Inc. (b)(e)
|
491,746
|
3,860,206
|
|
Moderna, Inc. (b)
|
376,651
|
29,265,783
|
|
Monte Rosa Therapeutics, Inc. (b)
|
939,805
|
2,913,396
|
|
Moonlake Immunotherapeutics (a)(b)
|
272,141
|
11,949,711
|
|
Morphic Holding, Inc. (b)
|
1,122,599
|
26,605,596
|
|
Morphimmune, Inc. (f)
|
434,782
|
3,243,474
|
|
Mural Oncology PLC
|
34,663
|
125,133
|
|
Natera, Inc. (b)
|
392,632
|
21,967,760
|
|
Neurocrine Biosciences, Inc. (b)
|
3,600
|
419,724
|
|
Nurix Therapeutics, Inc. (a)(b)
|
265,946
|
1,654,184
|
|
Nuvalent, Inc. Class A (b)
|
234,474
|
15,327,565
|
|
Omega Therapeutics, Inc. (a)(b)
|
367,803
|
842,269
|
|
Oragenics, Inc. (b)
|
2,597
|
9,297
|
|
ORIC Pharmaceuticals, Inc. (b)
|
117,400
|
927,460
|
|
PepGen, Inc. (b)
|
736,995
|
3,611,276
|
|
Poseida Therapeutics, Inc. (b)
|
223,383
|
596,433
|
|
Prelude Therapeutics, Inc. (b)
|
254,056
|
840,925
|
|
Protagonist Therapeutics, Inc. (b)
|
422,313
|
7,690,320
|
|
Prothena Corp. PLC (a)(b)
|
801,417
|
26,110,166
|
|
PTC Therapeutics, Inc. (b)
|
670,511
|
15,435,163
|
|
Rallybio Corp. (a)(b)
|
1,194,119
|
2,280,767
|
|
RAPT Therapeutics, Inc. (b)
|
802,700
|
11,655,204
|
|
RayzeBio, Inc. (a)
|
231,200
|
5,521,056
|
|
Recursion Pharmaceuticals, Inc. (a)(b)
|
149,900
|
1,026,815
|
|
Regeneron Pharmaceuticals, Inc. (b)
|
211,449
|
174,193,801
|
|
Regulus Therapeutics, Inc. (a)(b)(e)
|
2,922,600
|
3,857,832
|
|
Replimune Group, Inc. (b)
|
825,115
|
9,224,786
|
|
Revolution Medicines, Inc. (a)(b)
|
758,998
|
17,707,423
|
|
Rhythm Pharmaceuticals, Inc. (a)(b)
|
786,903
|
26,306,167
|
|
Rocket Pharmaceuticals, Inc. (b)
|
445,236
|
10,387,356
|
|
Roivant Sciences Ltd. (a)(b)
|
4,602,719
|
44,001,994
|
|
Sage Therapeutics, Inc. (b)
|
579,852
|
11,353,502
|
|
Sagimet Biosciences, Inc. (a)
|
63,660
|
243,181
|
|
Sana Biotechnology, Inc. (a)(b)
|
942,194
|
3,825,308
|
|
Sarepta Therapeutics, Inc. (b)
|
392,699
|
31,918,575
|
|
Scholar Rock Holding Corp. (a)(b)
|
2,486,576
|
31,305,992
|
|
Scholar Rock Holding Corp. warrants 12/31/25 (b)(f)
|
17,850
|
117,117
|
|
Sensorion SA (a)(b)
|
1,560,440
|
849,269
|
|
Seres Therapeutics, Inc. (a)(b)
|
854,347
|
888,521
|
|
Shattuck Labs, Inc. (b)
|
110,936
|
217,435
|
|
SpringWorks Therapeutics, Inc. (a)(b)
|
428,411
|
13,019,410
|
|
Tango Therapeutics, Inc. (b)
|
563,788
|
4,284,789
|
|
Tango Therapeutics, Inc. (f)
|
466,637
|
3,546,441
|
|
Taysha Gene Therapies, Inc. (a)(b)(e)
|
10,992,802
|
19,347,332
|
|
Tenaya Therapeutics, Inc. (b)
|
1,477,379
|
2,777,473
|
|
TG Therapeutics, Inc. (a)(b)
|
1,158,520
|
14,840,641
|
|
Turnstone Biologics Corp.
|
99,400
|
216,692
|
|
Twist Bioscience Corp. (a)(b)
|
274,525
|
6,602,326
|
|
Tyra Biosciences, Inc. (b)
|
109,900
|
1,286,929
|
|
Ultragenyx Pharmaceutical, Inc. (b)
|
1,039,430
|
40,381,856
|
|
uniQure B.V. (a)(b)
|
40,208
|
272,610
|
|
United Therapeutics Corp. (b)
|
251,869
|
60,448,560
|
|
Vaxcyte, Inc. (b)
|
1,039,280
|
53,803,526
|
|
Vera Therapeutics, Inc. (a)(b)
|
557,582
|
7,555,236
|
|
Vertex Pharmaceuticals, Inc. (b)
|
437,309
|
155,161,606
|
|
Verve Therapeutics, Inc. (a)(b)
|
208,593
|
2,352,929
|
|
Vigil Neuroscience, Inc. (b)
|
140,325
|
446,234
|
|
Viking Therapeutics, Inc. (a)(b)
|
417,052
|
5,096,375
|
|
Viridian Therapeutics, Inc. (b)
|
260,700
|
4,364,118
|
|
Vor Biopharma, Inc. (a)(b)
|
1,114,702
|
2,062,199
|
|
X4 Pharmaceuticals, Inc. warrants 4/12/24 (b)
|
450,000
|
5
|
|
Xencor, Inc. (b)
|
19,243
|
352,917
|
|
Xenon Pharmaceuticals, Inc. (b)
|
518,134
|
18,953,342
|
|
Zealand Pharma A/S (b)
|
661,102
|
32,434,169
|
|
Zentalis Pharmaceuticals, Inc. (b)
|
604,133
|
6,796,496
|
|
3,689,646,659
|
|||
Consumer Staples Distribution & Retail - 0.0%
|
|||
Drug Retail - 0.0%
|
|||
MedAvail Holdings, Inc. (b)
|
55
|
123
|
|
Health Care Equipment & Supplies - 0.0%
|
|||
Health Care Equipment - 0.0%
|
|||
Aradigm Corp. (b)(d)
|
148,009
|
1
|
|
Aradigm Corp. (b)(d)
|
11,945
|
0
|
|
Glaukos Corp. (b)
|
5,700
|
364,173
|
|
Novocure Ltd. (b)
|
11,113
|
136,357
|
|
500,531
|
|||
Health Care Providers & Services - 0.0%
|
|||
Health Care Services - 0.0%
|
|||
23andMe Holding Co. Class A (a)(b)
|
274,674
|
236,357
|
|
Health Care Technology - 0.4%
|
|||
Health Care Technology - 0.4%
|
|||
Schrodinger, Inc. (b)
|
495,801
|
15,414,453
|
|
Life Sciences Tools & Services - 0.3%
|
|||
Life Sciences Tools & Services - 0.3%
|
|||
10X Genomics, Inc. (b)
|
252,200
|
10,975,744
|
|
Pharmaceuticals - 5.2%
|
|||
Pharmaceuticals - 5.2%
|
|||
Adimab LLC (b)(d)(f)(g)
|
1,954,526
|
46,674,081
|
|
Afferent Pharmaceuticals, Inc. rights 12/31/24 (b)(d)
|
8,274,568
|
1,654,914
|
|
Amylyx Pharmaceuticals, Inc. (b)
|
577,300
|
8,174,568
|
|
Arvinas Holding Co. LLC (a)(b)
|
200,616
|
4,407,534
|
|
Atea Pharmaceuticals, Inc. (b)
|
66,800
|
199,732
|
|
Axsome Therapeutics, Inc. (a)(b)
|
223,003
|
15,041,552
|
|
Corcept Therapeutics, Inc. (b)
|
649,836
|
16,551,323
|
|
CymaBay Therapeutics, Inc. (b)
|
22,300
|
426,599
|
|
Edgewise Therapeutics, Inc. (b)
|
217,485
|
1,322,309
|
|
Enliven Therapeutics, Inc. (b)
|
122,500
|
1,379,350
|
|
Fulcrum Therapeutics, Inc. (b)
|
1,558,397
|
7,480,306
|
|
GH Research PLC (a)(b)
|
369,624
|
2,306,454
|
|
Harmony Biosciences Holdings, Inc. (b)
|
52,125
|
1,514,753
|
|
Ikena Oncology, Inc. (b)
|
230,227
|
333,829
|
|
Indivior PLC (b)
|
43,400
|
705,699
|
|
Intra-Cellular Therapies, Inc. (b)
|
170,299
|
10,451,250
|
|
Longboard Pharmaceuticals, Inc. (a)(b)
|
547,414
|
2,058,277
|
|
Novo Nordisk A/S Series B sponsored ADR
|
71,300
|
7,261,192
|
|
Nuvation Bio, Inc. (b)
|
4,966,826
|
6,158,864
|
|
OptiNose, Inc. (b)
|
794,031
|
992,539
|
|
OptiNose, Inc. warrants (b)
|
91,712
|
25,501
|
|
Pharvaris BV (b)
|
178,907
|
3,078,989
|
|
Pliant Therapeutics, Inc. (b)
|
37,431
|
519,917
|
|
Structure Therapeutics, Inc. (f)
|
228,801
|
4,247,308
|
|
Structure Therapeutics, Inc. ADR
|
192,497
|
10,720,158
|
|
Terns Pharmaceuticals, Inc. (b)
|
226,996
|
1,010,132
|
|
UCB SA
|
376,708
|
27,817,565
|
|
Verona Pharma PLC ADR (a)(b)
|
1,339,501
|
18,110,054
|
|
Verrica Pharmaceuticals, Inc. (a)(b)
|
1,508,769
|
5,552,270
|
|
WAVE Life Sciences (b)
|
585,633
|
3,109,711
|
|
209,286,730
|
|||
TOTAL COMMON STOCKS
(Cost $3,116,501,973)
|
3,926,060,597
|
||
Convertible Preferred Stocks - 1.4%
|
|||
Shares
|
Value ($)
|
||
Biotechnology - 1.3%
|
|||
Biotechnology - 1.3%
|
|||
ElevateBio LLC Series C (b)(d)(f)
|
216,600
|
651,966
|
|
National Resilience, Inc. Series B (b)(d)(f)
|
732,064
|
44,458,247
|
|
SalioGen Therapeutics, Inc. Series B (b)(d)(f)
|
94,461
|
5,526,913
|
|
50,637,126
|
|||
Health Care Providers & Services - 0.1%
|
|||
Health Care Services - 0.1%
|
|||
Scorpion Therapeutics, Inc. Series B (b)(d)(f)
|
3,099,905
|
4,122,874
|
|
Pharmaceuticals - 0.0%
|
|||
Pharmaceuticals - 0.0%
|
|||
Afferent Pharmaceuticals, Inc. Series C (b)(d)(f)
|
8,274,568
|
83
|
|
TOTAL CONVERTIBLE PREFERRED STOCKS
(Cost $28,408,650)
|
54,760,083
|
||
Money Market Funds - 7.0%
|
|||
Shares
|
Value ($)
|
||
Fidelity Cash Central Fund 5.40% (h)
|
9,253,862
|
9,255,713
|
|
Fidelity Securities Lending Cash Central Fund 5.39% (h)(i)
|
273,809,012
|
273,836,393
|
|
TOTAL MONEY MARKET FUNDS
(Cost $283,065,495)
|
283,092,106
|
||
TOTAL INVESTMENT IN SECURITIES - 106.3%
(Cost $3,427,976,118)
|
4,263,912,786
|
NET OTHER ASSETS (LIABILITIES) - (6.3)%
|
(252,131,749)
|
NET ASSETS - 100.0%
|
4,011,781,037
|
(a)
|
Security or a portion of the security is on loan at period end.
|
(b)
|
Non-income producing
|
(c)
|
Security exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $8,105,839 or 0.2% of net assets.
|
(d)
|
Level 3 security
|
(e)
|
Affiliated company
|
(f)
|
Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $146,773,584 or 3.7% of net assets.
|
(g)
|
Investment is owned by a wholly-owned subsidiary (Subsidiary) that is treated as a corporation for U.S. tax purposes.
|
(h)
|
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
|
(i)
|
Investment made with cash collateral received from securities on loan.
|
Additional information on each restricted holding is as follows:
|
||
Security
|
Acquisition Date
|
Acquisition Cost ($)
|
Adimab LLC
|
9/17/14 - 6/05/15
|
31,407,838
|
Afferent Pharmaceuticals, Inc. Series C
|
7/01/15
|
0
|
BridgeBio Pharma, Inc.
|
9/25/23
|
20,000,036
|
Cyclerion Therapeutics, Inc.
|
4/02/19
|
1,404,026
|
Dianthus Therapeutics, Inc. (unlisted)
|
5/03/23
|
3,022,111
|
ElevateBio LLC Series C
|
3/09/21
|
908,637
|
Fusion Pharmaceuticals, Inc.
|
2/13/23
|
5,042,200
|
Korro Bio, Inc.
|
7/14/23
|
5,000,000
|
Morphimmune, Inc.
|
6/29/23
|
2,499,997
|
National Resilience, Inc. Series B
|
12/01/20
|
9,999,994
|
SalioGen Therapeutics, Inc. Series B
|
12/10/21
|
10,000,019
|
Scholar Rock Holding Corp. warrants 12/31/25
|
6/17/22
|
0
|
Scorpion Therapeutics, Inc. Series B
|
1/08/21
|
7,500,000
|
Structure Therapeutics, Inc.
|
9/29/23
|
2,857,724
|
Tango Therapeutics, Inc.
|
8/09/23
|
2,403,181
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
% ownership,
end
of period
|
Fidelity Cash Central Fund 5.40%
|
16,575,392
|
634,946,158
|
642,265,837
|
489,094
|
-
|
-
|
9,255,713
|
0.0%
|
Fidelity Securities Lending Cash Central Fund 5.39%
|
353,621,750
|
1,215,786,222
|
1,295,571,579
|
3,412,459
|
7,030
|
(7,030)
|
273,836,393
|
1.0%
|
Total
|
370,197,142
|
1,850,732,380
|
1,937,837,416
|
3,901,553
|
7,030
|
(7,030)
|
283,092,106
|
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
Adverum Biotechnologies, Inc.
|
5,380,026
|
-
|
2,378,203
|
-
|
209,165
|
1,537,288
|
4,748,276
|
Applied Therapeutics, Inc.
|
2,665,931
|
-
|
500,709
|
-
|
327,550
|
2,629,118
|
-
|
Gossamer Bio, Inc.
|
-
|
6,942,725
|
-
|
-
|
-
|
2,570,451
|
9,513,176
|
IGM Biosciences, Inc.
|
14,514,499
|
12,882,266
|
2,444,779
|
-
|
(6,919,865)
|
(6,651,752)
|
11,380,369
|
Krystal Biotech, Inc.
|
171,824,409
|
-
|
9,387,317
|
-
|
942,317
|
43,529,857
|
206,909,266
|
Minerva Neurosciences, Inc.
|
-
|
4,240,089
|
-
|
-
|
-
|
(379,883)
|
3,860,206
|
Regulus Therapeutics, Inc.
|
2,941,300
|
1,143,299
|
-
|
-
|
-
|
(226,767)
|
3,857,832
|
Taysha Gene Therapies, Inc.
|
-
|
14,144,020
|
-
|
-
|
-
|
-
|
-
|
Taysha Gene Therapies, Inc.
|
819,763
|
-
|
15,822,933
|
-
|
(1,142,524)
|
21,349,006
|
19,347,332
|
Total
|
198,145,928
|
39,352,399
|
30,533,941
|
-
|
(6,583,357)
|
64,357,318
|
259,616,457
|